Skip to main content

Table 1 Clinical and radiological characteristics between lung adenocarcinoma patients with ALK positive (+) and ALK negative (-) in the training and validation sets 1–3

From: Intratumoral and peritumoral CT radiomics in predicting anaplastic lymphoma kinase mutations and survival in patients with lung adenocarcinoma: a multicenter study

Characteristics

Training set (n = 156)

Validation set 1 (n = 93)

Validation set 2 (n = 139)

Validation set 3 (n = 117)

ALK (-)

(n = 121)

ALK (+)

(n = 35)

P-value

ALK (-)

(n = 70)

ALK (+)

(n = 23)

P-value

ALK (-)

(n = 114)

ALK (+)

(n = 25)

P-value

ALK (-)

(n = 93)

ALK (+)

(n = 24)

P-value

Age, years*

59.44 ± 9.20

57.97 ± 11.93

0.440

61.34 ± 10.03

59.61 ± 10.83

0.482

58.11 ± 13.96

56.12 ± 15.34

0.528

60.26 ± 11.61

56.88 ± 11.72

0.207

Sex (%)

  

0.445

  

0.358

  

0.872

  

0.838

 Male

50 (41.32)

17 (48.57)

 

32 (45.71)

8 (34.78)

 

43 (37.72)

9 (36.00)

 

37 (37.72)

9 (36.00)

 

 Female

71 (58.68)

18 (51.43)

 

38 (54.29)

15 (65.22)

 

71 (62.28)

16 (64.00)

 

56 (62.28)

15 (64.00)

 

Smoking history (%)

  

0.254

  

0.643

  

0.239

  

0.221

 Yes

24 (19.83)

4 (11.43)

 

15 (21.43)

6 (26.09)

 

24 (21.05)

8 (32.00)

 

27 (29.03)

4 (16.67)

 

 No

97 (80.17)

31 (88.57)

 

55 (78.57)

17 (73.91)

 

90 (78.95)

17 (68.00)

 

66 (70.97)

20 (83.33)

 

Clinical TNM stage (%)

  

0.001

  

0.004

  

0.053

  

0.181

 I-III

101 (83.47)

20 (57.14)

 

63 (90.00)

14 (60.87)

 

93 (81.58)

16 (64.00)

 

74 (79.57)

16 (66.67)

 

 IV

20 (16.53)

15 (42.86)

 

7 (10.00)

9 (39.13)

 

21 (18.42)

9 (36.00)

 

19 (20.43)

8 (33.33)

 

Margin (%)

  

0.208

  

0.348

  

0.762

  

0.171

 Unclear

38 (31.40)

15 (42.86)

 

29 (41.43)

7 (30.43)

 

33 (28.95)

8 (32.00)

 

22 (23.66)

9 (37.50)

 

 Clear

83 (68.60)

20 (57.14)

 

41 (58.57)

16 (69.57)

 

81 (79.82)

17 (68.00)

 

71 (76.34)

15 (62.50)

 

Density (%)

  

0.049

  

0.002

  

0.159

  

0.086

 Solid

36 (29.75)

18 (51.43)

 

13 (18.57)

13 (56.52)

 

23 (17.54)

9 (44.00)

 

23 (24.73)

10 (41.67)

 

 Part-solid

43 (35.54)

7 (20.00)

 

32 (45.71)

5 (21.74)

 

57 (40.35)

8 (28.00)

 

46 (49.46)

6 (25.00)

 

 Pure GGO

42 (34.71)

10 (28.57)

 

25 (35.72)

5 (21.74)

 

34 (42.11)

8 (28.00)

 

24 (25.81)

8 (33.33)

 

Lobulation sign (%)

  

0.902

  

0.207

  

0.767

  

0.539

 Yes

47 (38.84)

14 (40.00)

 

29 (41.43)

13 (56.52)

 

51 (44.74)

12 (48.00)

 

53 (56.99)

12 (50.00)

 

 No

74 (61.16)

21 (60.00)

 

41 (58.57)

10 (43.48)

 

63 (55.26)

13 (52.00)

 

40 (43.01)

12 (50.00)

 

Spicule sign (%)

  

0.590

  

0.752

  

0.925

  

0.349

 Yes

44 (36.36)

11 (31.43)

 

16 (22.86)

6 (26.09)

 

33 (28.95)

7 (28.00)

 

24 (25.81)

4 (16.67)

 

 No

77 (63.64)

24 (68.57)

 

54 (77.14)

17 (73.91)

 

81 (71.05)

18 (72.00)

 

69 (74.19)

20 (83.33)

 

Pleural indentation (%)

  

< 0.001

  

0.002

  

0.064

  

0.036

 Yes

38 (31.40)

23 (65.71)

 

18 (25.71)

14 (60.87)

 

41 (16.67)

14 (56.00)

 

29 (31.18)

13 (54.17)

 

 No

83 (68.60)

12 (34.29)

 

52 (74.29)

9 (39.13)

 

73 (83.33)

11 (44.00)

 

64 (68.82)

11 (45.83)

 

Air bronchogram sign (%)

  

0.136

  

0.977

  

0.100

  

0.965

 Yes

32 (26.45)

5 (14.29)

 

13 (18.57)

5 (21.74)

 

23 (20.18)

1 (4.00)

 

19 (20.43)

5 (20.83)

 

 No

89 (73.55)

30 (85.71)

 

57 (81.43)

18 (78.26)

 

91 (79.82)

24 (96.00)

 

74 (79.57)

19 (79.17)

 

Vacuole sign (%)

  

0.521

  

0.095

  

0.973

  

0.395

 Yes

23 (19.01)

5 (14.29)

 

11 (15.71)

8 (34.78)

 

27 (23.68)

6 (24.00)

 

14 (15.05)

6 (25.00)

 

 No

98 (80.99)

30 (85.71)

 

59 (84.29)

15 (65.22)

 

87 (76.32)

19 (76.00)

 

79 (84.95)

18 (75.00)

 
  1. Note:*Continuous values expressed as the mean ± standard deviation
  2. Abbreviations: ALK, anaplastic lymphoma kinase; GGO, ground-glass opacity; TNM, Tumor Node Metastasis
Back to article page

Cancer Imaging

ISSN: 1470-7330

Contact us